Literature DB >> 9342757

Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas.

K Dietzmann1, P von Bossanyi, M Warich-Kirches, E Kirches, H J Synowitz, R Firsching.   

Abstract

The arachnoideal compartment provides the vascular sources for three different tumor types rich in vessels: angiomatous meningioma, some atypical meningioma with high vascularity and meningeal hemangiopericytoma. We investigated immunohistochemically the expression and distribution of vascular mitogenes in 7 angiomatous meningiomas, 8 atypical meningiomas with high vasculature and 4 hemangiopericytomas. On the one hand it should be studied which vascular growth factors such as VPF/VEGF-1, VPF/VEGF-2, bFGF, PDGF and TGF-alpha could be responsible for the close meshwork of vessels within the tumors. On the other hand we were interested in whether or not there are differences in vascular mitogens between slowly growing angiomatous meningiomas and both other types with their increased tendency to recur. PDGF and TGF-alpha were extensively expressed in the endothelium and smooth muscle cells of the vessels, as well as tumor cells. VEGF-2 could only be found in endothelial cells of all three tumor entities. bFGF was localized in some vessels of angiomatous meningiomas and VEGF-1 revealed a very low expression with a localization comparable with VEGF-2. Moreover, uPAR was diffusely expressed in nearly all tumor cells and endothelial cells. The fact that tumor cells of hemangiopericytomas and meningiomas did not show any immunohistochemical reaction with VEGF's could indicate a lower priority of these growth factors for neovascularization in this type of neoplasm. A different expression of vascular mitogens between benign angiomatous meningiomas and atypical meningiomas as well as hemangiopericytomas with their tendency for recurrence could not be observed. The morphological evidence for extravasates of IgG-proteins, Fibrin and Fibronectin due to VPF-effects seems not to be a renouncable condition for neoangiogenesis in the tumors investigated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342757     DOI: 10.1016/s0344-0338(97)80104-5

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Hemangiopericytoma in pregnancy: a case report.

Authors:  Mangiola Annunziato; Albanese Alessio; Mannino Stefano; Guerriero Massimiliano; Gessi Marco; Anile Carmelo; Maira Giulio
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

2.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 3.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

4.  Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease.

Authors:  T Hansen; A Gaumann; M Ghalibafian; A Höferlin; A Heintz; C J Kirkpatrick
Journal:  Virchows Arch       Date:  2004-07-09       Impact factor: 4.064

5.  Clinical characteristics and treatment of angiomatous meningiomas: a report of 27 cases.

Authors:  Zhiguo Liu; Chuanwei Wang; Hongwei Wang; Yunyan Wang; Jian Yi Li; Yuguang Liu
Journal:  Int J Clin Exp Pathol       Date:  2013-03-15

6.  Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature.

Authors:  M Delgado; E Pérez-Ruiz; J Alcalde; D Pérez; R Villatoro; A Rueda
Journal:  Case Rep Oncol       Date:  2011-02-05

7.  Regression of dural arteriovenous fistulae after venous flow reconstructive surgery in a case with hemangiopericytoma at the confluence of sinuses.

Authors:  Kota Kurisu; Hiroaki Motegi; Toshiya Osanai; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
Journal:  Case Rep Neurol       Date:  2014-08-07

8.  Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma.

Authors:  Su Jin Lee; Seung Tae Kim; Se Hoon Park; Yoon La Choi; Jae Berm Park; Sung-Joo Kim; Jeeyun Lee
Journal:  Clin Sarcoma Res       Date:  2014-09-24

9.  Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Authors:  Katherine B Peters; Roger McLendon; Michael A Morse; James J Vredenburgh
Journal:  Case Rep Oncol       Date:  2010-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.